Printer Friendly

BURROUGHS WELLCOME, DUKE TEAM UP IN CANCER RESEARCH

 BURROUGHS WELLCOME, DUKE TEAM UP IN CANCER RESEARCH
 RESEARCH TRIANGLE PARK, N.C., Feb. 27 /PRNewswire/ -- In a


partnership that epitomizes the spirit of the Research Triangle Park, Burroughs Wellcome Co. and Duke University Medical Center have announced a $5 million research collaboration that could result in progress in the fight against cancer.
 Under the research collaboration agreement, Burroughs Wellcome and Duke scientists will work together to develop products and technologies in the area of oncology, with special emphasis on targeted monoclonal antibodies.
 "This is the largest collaboration with a major university that Burroughs Wellcome has ever undertaken," said Dr. David W. Barry, Vice President of Research, Development and Medical Affairs at Burroughs Wellcome. "It is an excellent example of how the private sector and academia can work together."
 Dr. Ralph Snyderman, Chancellor for Health Affairs of Duke Medical Center, echoed Dr. Barry's sentiments. "We are extremely pleased to have established this partnership with Burroughs Wellcome in this most important research area. The medical center is dedicated to facilitating the application of its research discoveries to the betterment of mankind. This collaboration will allow us to couple our laboratory and clinical research progress with Wellcome's research, development, and scale-up capabilities to bring valuable therapeutics to clincial applicability as quickly as possible."
 Barry noted that although Burroughs Wellcome is best known for its antiviral research, the company has long had research programs in cancer. This work has led to a number of significant medications, and was recognized when Drs. George Hitchings and Gertrude Elion received the Nobel Prize for Medicine in 1988.
 Cancer Collaboration
 The oncology collaboration will be primarily devoted to research, preclinical studies and some early clinical investigations of potential monoclonal antibody-based products with special emphasis directed toward the treatment of neurologic and solid tumors.
 "We hope that the work performed under this collaboration also will include the development of agents for the diagnosis and treatment of lymphomas, solid tumors and compartmentalized tumors, including those of the central nervous system," said Dr. Thomas A. Krenitsky, Vice President of Research at Burroughs Wellcome.
 Krenitsky said Duke has particular expertise in the development of radiolabelled monoclonal antibodies which may be useful in the diagnosis and treatment of cancer. Wellcome has a genetically engineered antibody called Campath-1H(TM) and a synthetic small molecule that will be studied under the collaboration. Campath-1H is a humanized monoclonal antibody currently undergoing studies of its potential usefulness in treating lymphomas.
 Because nearly all of the Campath molecule is of human origin, it is unlikely to stimulate an immune response. This means, if effective, it should be possible to give repeated doses of Campath-1H to treat diseases that involve aberrant immune cells.
 The principal investigators from Duke are Darell D. Bigner, M.D., Ph.D., Edwin L. Jr. and Lucille Finch Jones Cancer Research Professor of Pathology (Neuropathology), and Michael R. Zalutsky, Ph.D., Professor of Radiology. Both are members of the Duke Comprehensive Cancer Center and are leaders in their respective fields of neuro-oncology and radiolabel conjugation technologies. They will work with a team of Wellcome researchers headed by Drs. James Burchall and Steven Jacobs.
 The $5 million collaboration will be funded for an initial three year term. "This is a significant agreement which exemplified Duke Medical Center's commitment to foster synergy in mutually beneficial areas with the biomedical research community. Our increasing number and diversity of interactions with the pharmaceutical and biotechnology industries in discovery, pre-clinical and clinical research is a testimony to the quality and scope of our resources and faculty," says Alan G. Herosian of the Medical Center's Office of Science and Technology.
 Wellcome Research
 Burroughs Wellcome is a research-based pharmaceutical company which established its headquarters in the Research Triangle Park in 1970. The company is a wholly owned subsidiary of The Wellcome Foundation Ltd. (Welcome plc), an international pharmaceutical company headquartered in London.
 Last year, Wellcome invested $409 million in research and development with 12 percent of that total invested in the anticancer therapeutic area.
 Burroughs Wellcome currently markets six medications used in the treatment of cancer: Alkeran(R) brand melphalian; Leukeran(R) brand chlorambucil; Myleran(R) brand busulfan; Purinethol(R) brand mercaptopurine; Tabloid(R) brand thioguanine and Wellcovorin(R) brand leucovorin calcium.
 -0- 2/27/92
 /CONTACT: Kathy S. Bartlett of Burroughs Wellcome Co., 919-248-4302/ CO: Burroughs Wellcome Co.; Duke University Medical Center ST: North Carolina IN: MTC SU: JVN


CM-JZ -- CH005 -- 3148 02/27/92 10:02 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 27, 1992
Words:738
Previous Article:MORE CLAIMS FILED IN LABOR DEPARTMENT PROBE INTO OFF-THE-CLOCK WORK AT FOOD LION
Next Article:BOSTON GLOBE TO OFFER FREE SITUATION WANTED ADVERTISEMENTS FOR UNEMPLOYED
Topics:


Related Articles
PILOT STUDY SUGGESTS SAFETY AND EFFECTIVENESS OF 566 A NEW INVESTIGATIONAL PCP THERAPY
ZOVIRAX(R) BENEFITS HEALTHY CHILDREN WITH CHICKENPOX
EXOSURF(R) NEONATAL(TM) LINKED TO INCREASED SURVIVAL IN LARGER INFANTS WITH RESPIRATORY DISTRESS SYNDROME
CYTRX CORPORATION ANNOUNCES THE INITIATION OF PHASE II STUDY SITES OF RHEOTHRX(R) INJECTION
AGGRESSIVE HIV STRAIN MAY CAUSE DISEASE PROGRESSION
NEW DATA DEMONSTRATE THAT RHEOTHRX(R) MAY ENHANCE ACTION OF THROMBOLYTICS IN TREATING HEART ATTACKS
NEW DATA DEMONSTRATE THAT RHEOTHRX MAY ENHANCE ACTION OF THROMBOLYTICS IN TREATING HEART ATTACKS
CYTRX: RHEOTHRX HEART ATTACK STUDY ONGOING
STUDY SHOWS NEW COMBINATION OF DRUGSMOST PROMISING WEAPON TO DATE IN FIGHTING HIV

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters